Evaluation of withdrawing growth hormone treatment in mid-puberty in stead of at final height in a group of growth hormone deficient adolescents

Assessing the cost-efectiveness of withdrawing growth hormone treatment after mid-puberty in adolescents with idiopathic isolated growth hormone deficiency

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26765

Enrollment

120

Registered

2017-08-15

Start date

2016-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

growth hormone deficiency growth hormone treatment cost-efficiency

Interventions

Withdrawing GH treatment in mid-puberty versus continuing GH treatment until near adult height (growth velocity <2 cm/yr)

Eligibility

Inclusion criteria

Inclusion criteria: idopathic isolated growth hormone deficiency GH peak at diagnosis > 5 mU/L and 12 ml and bone age 13-16 years; girls: Tanner B3 or B4, bone age 11-14 years) GH peak at retesting mid puberty > 20 mU/L Treated with GH for at least 3 years Informed consent

Exclusion criteria

Exclusion criteria: Medical condition or medication influencing growth

Design outcomes

Primary

Measure	Time frame
Adult height (AH) minus target height (TH) SDS.	—

Secondary

Measure	Time frame
Adult height SDS, total pubertal growth (cm), and satisfaction with attained adult height.	—

Contacts

Public ContactM.J.E. Walenkamp

m.walenkamp@vumc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)